# Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE

> **NCT03673943** · PHASE3 · COMPLETED · sponsor: **Radiomedix, Inc.** · enrollment: 63 (actual)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** 64Cu-DOTATATE

## Key facts

- **NCT ID:** NCT03673943
- **Lead sponsor:** Radiomedix, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-23
- **Primary completion:** 2019-03-23
- **Final completion:** 2019-08-07
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2022-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03673943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03673943, "Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03673943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*